The Barrier That Breaks First and the Peptide Designed to Hold It

Keywords: Larazotide Acetate, Intestinal Permeability, Tight Junction, Zonulin, Celiac Disease, Autoimmune

Introduction

The gastrointestinal epithelium serves as one of the most dynamic and immunologically active interfaces in the human body. Spanning approximately 400 m² in surface area, the gut mucosa must simultaneously facilitate nutrient absorption and exclude harmful luminal contents, a dual function achieved through a highly regulated epithelial barrier. Central to this barrier are intercellular tight junctions (TJs), protein complexes that seal the paracellular space between adjacent epithelial cells and restrict passage of macromolecules and microbial products into the lamina propria and systemic circulation [1,2].

When TJ integrity is compromised, the resulting increase in intestinal permeability allows translocation of lipopolysaccharide (LPS), bacterial fragments, undigested antigens, and other proinflammatory molecules. The immunological consequences extend far beyond the gut: systemic endotoxemia drives chronic low-grade inflammation, a hallmark of multiple non-communicable diseases including type 2 diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), inflammatory bowel disease (IBD), celiac disease, and a growing list of autoimmune conditions [3,4].

The discovery of zonulin, the first identified endogenous physiological regulator of intestinal TJ permeability in humans, represented a fundamental advance in understanding how the gut barrier is dynamically regulated. Zonulin upregulation in response to luminal triggers such as gliadin and bacterial components promotes TJ disassembly, and chronically elevated zonulin has been documented across a wide range of inflammatory and autoimmune phenotypes [5,6].

Larazotide acetate, a synthetic octapeptide originally derived from Vibrio cholerae Zot, was rationally designed to competitively block the zonulin receptor, thereby preventing TJ opening and maintaining epithelial barrier integrity. After more than two decades of preclinical development and clinical investigation, larazotide now stands as the most clinically validated pharmacological approach to TJ regulation. The recent publication of a randomized trial demonstrating its safety and efficacy in MIS-C in Science Translational Medicine (2025) has reignited interest in the broader therapeutic potential of TJ modulation [7,8].

This review provides a comprehensive, evidence-based synthesis of intestinal barrier biology, the zonulin-larazotide axis, clinical trial data across multiple disease states, and the emerging implications for longevity medicine and prevention of metabolic disease.

The Intestinal Epithelial Barrier: Architecture and Functional Significance

Structural Organization

The intestinal epithelium is a single-cell-layer-thick structure comprising enterocytes, goblet cells, enteroendocrine cells, Paneth cells, and microfold (M) cells. The physical integrity of this epithelium depends on three principal intercellular junctional complexes: TJs (most apical), adherens junctions, and desmosomes. Of these, TJs are the primary determinant of paracellular permeability [1,2].

Tight Junction Protein Composition

TJs are multi-protein complexes composed of transmembrane proteins which are claudins, occludin, and junctional adhesion molecules (JAMs), anchored to the perijunctional actomyosin ring via cytoplasmic scaffolding proteins, primarily zonula occludens-1 (ZO-1), ZO-2, and ZO-3.^[Barrier-forming claudins (e.g., claudin-1, -3, -4, -8) close the paracellular pathway, while pore-forming claudins (e.g., claudin-2, -15) create size- and charge-selective channels. Occludin regulates the leak pathway and serves as a signaling scaffold influencing TJ dynamics. ZO-1 links transmembrane TJ proteins to the actin cytoskeleton and has been implicated in regulation of epithelial proliferation and apoptosis [2,9].

Two-Pathway Model of Paracellular Permeability

Intestinal permeability is physiologically regulated through two distinct paracellular pathways. The pore pathway is a high-capacity, size-restricted (≤0.6 nm diameter), charge-selective channel primarily governed by claudin-2 and -15. The leak pathway is a low-capacity, non-charge-selective channel allowing movement of larger molecules (up to ~12.5 nm), regulated predominantly by occludin and myosin light chain kinase (MLCK)-mediated actomyosin contraction. Pathological increases in leak pathway flux underlie most clinically relevant instances of intestinal hyperpermeability [2,9].

Consequences of barrier Dysfunction

When TJ integrity is compromised, luminal content, including LPS (bacterial endotoxin), peptidoglycan, bacterial DNA, and undigested dietary antigens gain access to the lamina propria and systemic circulation.This triggers activation of Toll-like receptor-4 (TLR-4), nuclear factor kappa B (NF-κB) signaling, and production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. The resulting state of chronic, low-grade systemic inflammation often termed “metabolic endotoxemia” is now recognized as a mechanistic driver of insulin resistance, atherosclerosis, neurodegeneration, and accelerated biological aging [3,4,10].

Zonulin: The Molecular Gateway to Intestinal Permeability

Discovery and Identity

Zonulin was first described by Fasano and colleagues in 2000 as a novel modulator of intestinal TJ permeability, isolated in the context of celiac disease research. Its expression was found to be elevated in the intestinal mucosa of active celiac disease patients. Subsequently, zonulin was identified as prehaptoglobin-2, a precursor to the haptoglobin family of proteins, establishing it as an endogenous physiologically relevant regulator of gut permeability [5,11].

Triggers of Zonulin Release

Two major physiological triggers have been characterized for zonulin release from intestinal epithelial cells.Gliadin (wheat gluten fraction): gliadin binds to the chemokine receptor CXCR3 on intestinal epithelial cells, triggering MyD88-dependent zonulin secretion and subsequent TJ disassembly, a process that occurs in both celiac and non-celiac individuals, though with greater magnitude in genetically susceptible subjects. Luminal bacteria: bacterial exposure to the apical surface of small intestinal epithelial cells activates zonulin secretion as a host defense response. In chronic dysbiosis, persistent bacterial stimulation sustains zonulin elevation and perpetuates barrier dysfunction [5,6].

Signaling Mechanism

Upon secretion, zonulin binds to the epidermal growth factor receptor (EGFR) and protease-activated receptor-2 (PAR-2) on the basolateral surface of epithelial cells, initiating a signalling cascade involving phosphatidylinositol-3-kinase (PI3K), protein kinase C (PKC), and MLCK. MLCK-mediated phosphorylation of the myosin II regulatory light chain contracts the perijunctional actomyosin ring, physically pulling apart TJ strand proteins and opening the paracellular pathway [5,7].

Zonulin in Disease States

Elevated circulating and fecal zonulin levels have been documented in a broad spectrum of conditions.In celiac disease, zonulin is upregulated by gliadin exposure and persists even in patients on a strict gluten-free diet, correlating with residual mucosal inflammation. In type 1 diabetes, increased intestinal permeability and elevated zonulin have been identified prior to clinical disease onset, suggesting a role in the autoimmune cascade.Elevated zonulin has also been reported in IBD, irritable bowel syndrome (IBS), non-alcoholic steatohepatitis (NASH), schizophrenia, and multiple sclerosis, consistent with a cross-disease role for gut barrier dysfunction in driving systemic immune dysregulation [4-6,10].

Larazotide Acetate: Origin, Structure, and Mechanism of Action

Derivation and Chemistry

Larazotide acetate (formerly AT-1001) is a synthetic octapeptide (GGVLVQPG) derived from the Vibrio cholerae Zot protein, which was observed to open intestinal TJs through interaction with a host receptor, the same receptor later shown to respond to zonulin.Rather than mimicking Zot’s permeability-increasing action, larazotide was engineered as a competitive antagonist at this receptor, thereby blocking zonulin’s ability to induce TJ disassembly [7,12].

Mechanism of Action

Larazotide acts through two complementary, synergistic mechanisms [7,11,12].

Zonulin receptor antagonism: Larazotide competitively blocks zonulin binding to its receptor (EGFR/PAR-2 complex), preventing downstream PI3K/PKC/MLCK activation and thereby preserving TJ integrity in the presence of gliadin, bacterial triggers, or other zonulin-inducing stimuli.

Direct TJ stabilisation: Independent of zonulin blockade, larazotide promotes redistribution of TJ proteins, including occludin and claudin-3 from intracellular compartments back to the plasma membrane. It also inhibits MLCK directly, reducing actomyosin ring tension and facilitating TJ closure. The net result is restoration of epithelial barrier architecture and normalization of paracellular flux [7,12].

Pharmacokinetics and Oral Bioavailability

Larazotide is orally administered and acts locally within the gastrointestinal lumen and epithelium, with minimal systemic absorption, a pharmacokinetic feature that contributes to its favorable safety profile. Phase I studies demonstrated dose-proportional local action with no significant systemic accumulation at therapeutic doses (0.25–36 mg), and the molecule does not cross the blood-brain barrier or accumulate in peripheral tissues [12].

Clinical Evidence in Celiac Disease

Rationale for Celiac Disease

Celiac disease, affecting approximately 1% of the global population, is driven by an aberrant immune response to gluten in genetically susceptible (HLA-DQ2/DQ8-positive) individuals.The canonical model holds that gliadin-induced zonulin release opens intestinal TJs, allowing gliadin peptides to access the lamina propria, where tissue transglutaminase (tTG) deamidates them, enhancing immunogenicity and triggering CD4+ T-cell-mediated villous atrophy.Larazotide’s ability to block this upstream gliadin-zonulin-permeability axis positioned it as a rational adjunct therapy, particularly given that a strict gluten-free diet (GFD), the only current treatment is difficult to maintain and often fails to achieve complete mucosal healing [5-8].

Phase IIa Gluten Challenge Trials

The first RCT of larazotide in celiac disease, published by Leffler and colleagues in 2012, enrolled 184 patients with well-controlled disease who underwent a supervised gluten challenge.Larazotide at 1 mg three times daily (TID) significantly limited gluten-induced gastrointestinal symptoms versus placebo, as measured by the Gastrointestinal Symptom Rating Scale (GSRS; p = 0.002). Lactulose-to-mannitol (LAMA) ratio showed a numerical trend favoring larazotide but did not reach statistical significance [13].

A subsequent double-blind RCT by Kelly and colleagues (2013), enrolling 342 celiac patients, confirmed the symptomatic benefit of larazotide at the 4 mg dose during gluten challenge, again with a favorable tolerability profile.Neither study identified serious adverse events attributable to larazotide [14].

Phase IIb Trial in Symptomatic Celiac Disease on Gluten-Free Diet

The landmark phase IIb trial by Leffler and colleagues, published in Gastroenterology in 2015, randomized 342 patients with persistently symptomatic celiac disease despite adherence to a GFD to larazotide 0.5 mg, 1 mg, 2 mg TID or placebo for 12 weeks. The primary endpoint, reduction in weekly average abdominal pain score was met at the 0.5 mg dose, with a 26% decrease in symptomatic days (p < 0.05 vs. placebo), a 31% increase in improved symptom days, and ≥50% baseline abdominal pain reduction sustained for 6 or more of 12 weeks. The 1 mg and 2 mg doses did not outperform placebo, suggesting a non-linear dose-response potentially attributable to receptor saturation kinetics [15].

Systematic Review and Meta-Analytics

A 2021 systematic review and meta-analysis incorporating data from four RCTs (626 patients total, 465 on larazotide, 161 on placebo) confirmed that larazotide acetate was superior to placebo in alleviation of gastrointestinal symptoms, with a statistically significant pooled effect on symptom scores. Pooled analysis of LAMA ratios did not demonstrate a significant reduction in intestinal permeability by this biomarker, raising questions about whether LAMA ratio is an adequately sensitive permeability endpoint [16].

Phase III Program and Discontinuation

The phase III CedLara trial, initiated by 9 Meters BioPharma, enrolled patients with symptomatic celiac disease on GFD. An interim analysis in 2022 determined that the required sample size to achieve statistical significance would exceed feasibility for the sponsoring organization, and the program was discontinued on financial rather than safety or efficacy grounds.This development underscores a recurring challenge in rare disease drug development: proof-of-concept clinical signals can precede commercially viable phase III programs, particularly when orphan drug incentives are insufficient [17].

Expanding Indications: Autoimmune and Metabolic Conditions

The “Two-Hit” Hypothesis of Autoimmunity

A unifying hypothesis advanced by Fasano proposes that three conditions are necessary for autoimmune disease to develop: genetic susceptibility, environmental triggers, and increased intestinal permeability. Under this model, a permeable gut allows exposure of the mucosal immune system to luminal antigens, triggering autoreactive immune responses in genetically predisposed individuals. Normalization of intestinal barrier function, even after autoimmune processes are established may interrupt this cycle [5,18].

Type 1 Diabetes

Animal and human studies have identified increased intestinal permeability as a pre-clinical feature of type 1 diabetes (T1D), preceding clinical onset by months to years. Non-obese diabetic (NOD) mice display elevated intestinal permeability and zonulin prior to insulitis, and genetic or pharmacological TJ stabilization delays disease progression. In humans, first-degree relatives of T1D patients show higher LAMA ratios compared to controls, suggesting that barrier dysfunction may be a susceptibility marker. Larazotide has been proposed as a candidate intervention in at-risk individuals, though prospective human trials in T1D prevention remain in early planning stages [4,12,18].

Inflammatory Bowel Disease

In Crohn’s disease and ulcerative colitis, dysregulation of claudin-2, -5, and -8 expression leads to disrupted TJ strands, barrier failure, and sustained luminal antigen exposure driving mucosal inflammation. Preclinical data suggest larazotide reduces mucosal permeability and cytokine production in murine colitis models; however, no large-scale human RCTs in IBD have been published to date, representing a significant evidence gap [7,19].

Metabolic Endotoxemia, Obesity, and Type 2 Diabetes

Cani and colleagues demonstrated in 2008 that a high-fat diet in mice induces dysbiosis, reduces TJ expression (occludin and ZO-1), and increases circulating LPS, a state termed metabolic endotoxemia, which directly promotes adipose tissue inflammation, insulin resistance, and weight gain. In humans, elevated serum LPS and zonulin correlate with visceral adiposity, insulin resistance, and the severity of NAFLD.^] While no larazotide RCT in obesity or type 2 diabetes has been completed, the mechanistic rationale is well-grounded and warrants clinical investigation [3,10].

Hyperglycaemia as a Barrier-Disruptive Stimulus

Evidence from Thaiss and colleagues (Science, 2018) established that hyperglycaemia itself directly disrupts intestinal epithelial TJ proteins, creating a pathological feed-forward loop: metabolic dysfunction increases intestinal permeability, which drives further endotoxemia and inflammation, which worsens insulin resistance and glycaemic control. Larazotide’s potential to interrupt this cycle at the level of TJ regulation provides additional mechanistic rationale for its investigation in cardiometabolic disease [20].

Larazotide in Post-Viral Syndromes: MIS-C and Long COVID

SARS-CoV-2 and Intestinal Barrier Disruption

SARS-CoV-2 infects gastrointestinal epithelial cells via ACE2 receptors, which are highly expressed throughout the intestinal tract. Viral infection disrupts TJ proteins and increases intestinal permeability, allowing translocation of viral antigens, LPS, and proinflammatory cytokines into systemic circulation. Antigenemia, the persistence of SARS-CoV-2 spike protein in the bloodstream weeks to months after acute infection has been identified as a correlate of Long COVID symptom burden and MIS-C pathophysiology [8].

Phase 2a RCT in Multisystem Inflammatory Syndrome in Children (MIS-C)

The most significant recent advance in larazotide research was published in Science Translational Medicine in 2025 by investigators at Mass General Brigham. This phase 2a, randomized, double-blind, placebo-controlled trial enrolled 12 children (median age 5.7 years) hospitalized with acute MIS-C. Participants received adjuvant larazotide (oral, four times daily) or placebo for 21 days in addition to standard immunotherapy [8].

Children treated with larazotide demonstrated: faster clearance of circulating SARS-CoV-2 spike antigen; faster resolution of gastrointestinal symptoms; and earlier return to usual activities compared to placebo-treated controls. No larazotide-related adverse events were reported.The investigators proposed that larazotide strengthened the intestinal barrier, limiting ongoing spike antigen translocation from the gut lumen into systemic circulation, thereby accelerating resolution of the hyperinflammatory MIS-C phenotype [8].

Ongoing Trial in Long COVID (NCT05747534)

Building on the MIS-C findings, a Phase 2a randomized, double-blind, placebo-controlled trial (NCT05747534) is currently evaluating larazotide in children and adults aged 7–50 with Long COVID symptoms and evidence of SARS-CoV-2 antigenemia, with participants receiving larazotide or placebo four times daily for 21 days.The trial’s mechanistic hypothesis mirrors the MIS-C rationale: barrier restoration limits ongoing spike antigen translocation, reduces systemic immune activation, and alleviates post-viral symptoms [21].

Intestinal Permeability, Aging, and Longevity

Age-Associated Gut barrier Decline

Accumulating evidence demonstrates that intestinal TJ integrity progressively deteriorates with advancing age, a phenomenon increasingly linked to the biology of “inflammaging” (chronic, low-grade, sterile inflammation associated with aging). Aged gut microbiota, characterised by reduced diversity, loss of SCFA-producing bacteria (e.g., Bifidobacterium, Faecalibacterium prausnitzii), and overgrowth of gram-negative proteobacteria, drives mucin layer thinning and TJ protein downregulation. The resulting increase in intestinal permeability elevates circulating LPS, amplifying systemic inflammation and contributing to vascular dysfunction, neurodegeneration, sarcopenia, and metabolic dysregulation, all hallmarks of accelerated biological aging [22].

Gut Microbiota as a Mediator

The interplay between gut microbiota composition, intestinal permeability, and metabolic health is bidirectional. Diet-induced dysbiosis reduces SCFA production, compromising TJ protein expression and mucosal immunity. Systemic LPS translocation further suppresses microbiota-protective secretory IgA (sIgA), creating a self-perpetuating cycle of barrier degradation and dysbiosis. Therapeutic strategies targeting gut barrier function including TJ stabilization with larazotide may therefore exert broad downstream benefits on microbiota composition, systemic inflammation, and longevity trajectories [3,10].

Implications for Preventive Longevity Medicine

The convergence of evidence from celiac disease, metabolic syndrome, autoimmunity, and post-viral syndromes points to intestinal barrier integrity as a modifiable determinant of systemic health and longevity. In the context of preventive longevity medicine, where early intervention in subclinical pathophysiology is paramount, pharmacological TJ stabilization represents a novel and mechanistically coherent strategy. Larazotide’s oral bioavailability, local action, and favorable safety profile make it a compelling candidate for investigation in high-risk metabolic and ageing populations, pending larger, adequately powered trials [12,15,22].

Safety Profile and Tolerability

Across all completed phase I–III trials, larazotide acetate has demonstrated a consistent and favorable safety profile. Single and multiple doses ranging from 0.25 mg to 36 mg in healthy volunteers produced no severe drug-related side effects. In celiac disease RCTs, adverse event rates were comparable between larazotide and placebo groups; the most frequently reported adverse events were headache and urinary tract infection, neither occurring at significantly higher rates in active treatment groups. No serious adverse events attributable to larazotide were reported in any completed trial, including the MIS-C paediatric study. The local, non-systemic mechanism of action with minimal systemic absorption, likely accounts for this tolerability advantage and distinguishes larazotide from systemic immunosuppressants or biologics currently used in inflammatory and autoimmune diseases [8,12-15].

Future Directions and Clinical Implications

Several key questions remain unresolved and define priority areas for future research. The optimal dose and dosing frequency across disease contexts requires further characterization. The non-linear dose-response observed in celiac disease (0.5 mg outperforming higher doses) highlights the complexity of TJ receptor pharmacology and warrants systematic exploration across disease phenotypes [15].

The discordance between symptom improvement and LAMA ratio normalisation in celiac RCTs raises fundamental questions about the relationship between permeability biomarkers and clinical outcomes. More sensitive biomarkers, including circulating claudin-3, occludin fragments, intestinal fatty acid binding protein (I-FABP), and fecal zonulin may better capture the therapeutic effect of larazotide [16].

Combination strategies stacking larazotide with microbiome-targeted interventions (prebiotics, probiotics, fecal microbiota transplantation) or dietary modification merit investigation as synergistic approaches to barrier restoration [3,12].

Finally, the extension to metabolic disease prevention, particularly in individuals with prediabetes, metabolic syndrome, or obesity with elevated zonulin represents a high-value and currently underexplored indication with significant public health relevance [10,20].

Conclusion

Larazotide acetate represents a scientifically grounded, clinically validated approach to modulating intestinal epithelial barrier function through selective antagonism of the zonulin receptor. Two decades of research have established its mechanistic basis, competitive blockade of zonulin-induced TJ disassembly and direct TJ protein stabilization and multiple RCTs in celiac disease have confirmed symptomatic efficacy and a favorable safety profile. More recently, a randomized trial in MIS-C published in Science Translational Medicine (2025) demonstrated that barrier restoration may accelerate clearance of circulating viral antigens and facilitate recovery from post-viral hyperinflammatory syndromes, a finding with significant implications for Long COVID management [8].

Viewed through the lens of systems biology and longevity medicine, the intestinal barrier emerges not merely as a gastrointestinal structure but as a master regulator of systemic inflammation, immune homeostasis, and metabolic health. Chronic disruption of TJ integrity, through dysbiosis, dietary triggers, hyperglycaemia, or aging drives the metabolic endotoxemia and immunological noise that underpin many of the most prevalent and burdensome non-communicable diseases of the twenty-first century [3,5,22].

Larazotide acetate, in targeting this upstream, cross-disease mechanism, offers a paradigm shift in how we conceptualize and potentially treat a diverse constellation of inflammatory, autoimmune, and metabolic conditions. Adequately powered trials in metabolic syndrome, type 2 diabetes prevention, and longevity-focused populations are urgently warranted to realize the full therapeutic potential of intestinal barrier restoration.

Reference

1. Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol. 2017;14(1):9-21.

2. Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. 2019;68(8):1516-26.

3. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57(6):1470-81.

4. Mu Q, Kirby J, Reilly CM, Luo XM. Leaky gut as a danger signal for autoimmune diseases. Front Immunol. 2017;8:598.

5. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011;91(1):151-75.

6. Drago S, El Asmar R, Di Pierro M, Grazia Clemente M, Tripathi A, Sapone A, et al. Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol. 2006;41(4):408-19.

7. Vanuytsel T, Senger S, Fasano A. Larazotide acetate: a pharmacological peptide approach to tight junction regulation. Am J Physiol Gastrointest Liver Physiol. 2021;321(2):G130-40.

8. Umans BD, Bhatt AS, Bhatt DL, et al. Viral spike antigen clearance and augmented recovery in children with post-COVID multisystem inflammatory syndrome treated with larazotide. Sci Transl Med. 2025;17:eadu4284.

9. Kuo WT, Zuo L, Odenwald MA, Shen L, Turner JR. Tight junction proteins occludin and ZO-1 as regulators of epithelial proliferation and survival. Ann N Y Acad Sci. 2022;1514(1):44-55.

10. Sonnenburg JL, Backhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016;535(7610):56-64.

11. Tripathi A, Lammers KM, Goldblum S, Shea-Donohue T, Netzel-Arnett S, Buzza MS, et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci USA. 2009;106(39):16799-804.

12. Khaleghi S, Ju JM, Lamba A, Murray JA. The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate. Therap Adv Gastroenterol. 2016;9(1):37-49.

13. Leffler DA, Kelly CP, Abdallah HZ, Colatrella AM, Harris LA, Leon F, et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol. 2012;107(10):1554-62.

14. Kelly CP, Green PH, Murray JA, DiMarino A, Colatrella A, Leffler DA, et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo-controlled study. Aliment Pharmacol Ther. 2013;37(2):252-62.

15. Leffler DA, Kelly CP, Green PH, Fedorak RN, DiMarino A, Perrow W, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. Gastroenterology. 2015;148(7):1311-9.

16. Venuprasad K, Balasubramanian H, Murray JA. Larazotide acetate for treatment of celiac disease: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2021;46:219-27.

17. Beyond Celiac. Phase 3 study of larazotide acetate to treat celiac disease discontinued [Internet]. 2022 [cited 2026 Jun 15]. Available from: https://www.beyondceliac.org/research-news/phase-3-study-discontinued/

18. Mishra A, Bhowmick M, Bhatt T, Singh S, Paliwal A. Gut microbiota, leaky gut, and autoimmune diseases. Front Immunol. 2022;13:946248.

19. Zeissig S, Burgel N, Gunzel D, Richter J, Mankertz J, Wahnschaffe U, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease. Gut. 2007;56(1):61-72.

20. Thaiss CA, Levy M, Grosheva I, Zheng D, Soffer E, Blacher E, et al. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection. Science. 2018;359(6382):1376-83.

21. ClinicalTrials.gov. AT1001 for the treatment of Long COVID. Study NCT05747534 [Internet]. 2023 [cited 2026 Jun 15]. Available from: https://clinicaltrials.gov/study/NCT05747534

22. Prasad MR, Kumar A, Bhatt S. Leaky gut in systemic inflammation: exploring the link between gastrointestinal disorders and age-related diseases. J Inflamm Res. 2025;18:3401-15.